Sanofi pins future growth on vaccines and immunology

France's biggest drugmaker Sanofi (Euronext: SAN) has spent the last five years remaking itself. Once anchored in diabetes and cardiovascular drugs, the group now leans heavily on its vaccines unit and the breakout success of Dupixent (dupilumab) to power growth.

With diabetes franchises commoditized and cardiovascular bets scaled back, Sanofi’s long-term trajectory hinges on whether these two engines, vaccines and immunology, can sustain momentum and withstand looming pressures.

Twin pillars